| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 172.4 | 154.6 |
| Gross profit | 50.8 | 42.7 |
| Profit before tax | 26.1 | 21.1 |
| Net income | 20.6 | 16.4 |
| EPS (diluted, $ a share) | $2.64 | $2.11 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +25.8% |
|---|---|
| Revenue, year on year | +11.6% |
| Gross margin | 29.4% |
| Operating margin | 16.0% |
10-Q filed with the SEC, NASDAQ: UFPT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Ufp Technologies Inc: key numbers
- Share price
- $298.54Close, Nov 16
- Market cap
- $2.31B
- Shares outstanding
- 7.75MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Ufp Technologies Inc
All →Ufp Technologies Financial Results
UFP Technologies reported third quarter 2026 net income of $20.6 million on net sales of $172.4 million, representing 11.6% year-over-year growth. The results were driven by strong MedTech demand and organic sales growth of 11.1%, alongside scaling operations in the Dominican Republic.
- Term
- Q3 2026
“Our third quarter and year-to-date results reflect continued solid execution across the UFP platform and progress toward our long-term growth strategy. In the third quarter, sales grew 11.6%, including 11.1% organic growth, gross margins increased to 29.4%, and adjusted operating income grew 14.5%.”
Mitch Rock, President and Chief Executive Officer
“Looking ahead to 2027, we are optimistic about the strength and positioning of UFP. We have invested in additional capacity at DAS Medical to support double-digit growth and have continued to build and invest in the team.”
Mitch Rock, President and Chief Executive Officer